Patient Resources

The Sarcoma Foundation of America Clinical Trial Navigating Service

The Sarcoma Foundation of America Clinical Trial Navigating Service offers patients, caregivers and health care professionals up-to-date information about sarcoma cancer clinical trials throughout the United States and Canada. The service is provided in collaboration with EmergingMed and will help you quickly search for clinical trial options that match your specific diagnosis and treatment history.

This free and confidential service is designed to allow you to begin the search process online. However, we recommend that visitors begin the process by calling our toll-free number: 800-536-8718 or go to SFA Clinical Trial Navigating Service

Clinical Trials Resource Center

Welcome to the Sarcoma Foundation of America’s Clinical Trials Resource Center presented in partnership with CenterWatch.com, the leading publisher of information on clinical research for patients and their advocates. Please click on the links below to learn more about clinical research and new medical therapies.

Actively Recruiting Clinical Trials*

*for a comprehensive list, please go to the Patient Resource section at the bottom of the page.

Trabectedin or Dacarbazine for the Treatment of Patients with Advanced Liposarcoma or Leiomyosarcoma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and PharmaMar are conducting a Phase 3 clinical trial for trabectedin or dacarbazine in patients with liposarcoma or leiomyosarcoma. This is a randomized (study drug assigned by chance), open-label (all patients and study staff know the identity of the assigned study drug), active-controlled (comparing to a different drug used for the same condition), parallel-group (different treatment groups continue with separate treatments throughout the study), multicenter study. This study will be divided into three phases, screening, treatment, and follow-up. During screening, potential patients will be assessed for study eligibility after providing signed informed consent. During the treatment phase, patients will receive study drug once every 3 weeks, until disease progression or signs of toxicity. Assessments will be performed to evaluate the effectiveness of the drug, and patient safety will be monitored. During the follow-up phase, after the last dose of study drug, clinical outcomes for patients will be evaluated. Trabectedin will be administered at a dose of 1.5 mg/m2 through a catheter into a large vein as a 24-hour intravenous (IV) infusion, once every 3 weeks, until disease progression or signs of toxicity. Dacarbazine will be administered at a dose of 1.0 g/m2 as a 20-minute infusion, once every 3 weeks, until disease progression or signs of toxicity. For more information on this study, please visit http://www.l-sarcomastudy.com or http://www.clinicaltrials.gov (Identifier # NCT01343277).

IPI-926 for Chondrosarcoma

Infinity Pharmaceuticals activated a global, randomized, phase 2, double-blind trial of IPI-926 in patients with advanced chondrosarcoma. This ongoing trial will determine the safety and activity of IPI-926 compared to placebo in patients with metastatic or locally advanced conventional chondrosarcoma, in whom surgery is no longer an option. To be eligible, participants must be at least 18 years of age, have conventional chondrosarcoma and have experienced progression of their disease within 6 months prior to enrollment. For more details regarding this study, including more complete eligibility criteria and a list of participating centers, please go to the following link: clinical trial overview.

PICASSO: Phase 3 Randomized Control Trial now enrolling in Soft-Tissue Sarcoma

ZIOPHARM Oncology is now enrolling patients in a Phase III randomized controlled trial (RCT) of palifosfamide combined with doxorubicin for the treatment of patients with unresectable or metastatic soft-tissue sarcoma (STS): A Phase III multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO). 

Eligible patients have been diagnosed with advanced, histologically confirmed STS excluding alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcoma and unresectable low-grade liposarcoma and have front line or second line metastatic disease or advanced local disease.  Patients may have failed adjuvant therapy.  Additional information regarding the PICASSO trial for both patients and providers can be found at http://www.picasso3trial.com or http://www.clinicaltrial.gov. A listing of participating study sites can also be found at this website.

Trivalent Vaccine for Sarcoma

MabVax Therapeutics is actively recruiting patients for a Phase 2 sarcoma vaccine trial who have recently been treated for metastatic sarcoma and whose status is “No Evidence of Disease” or NED. The patients in the study will be randomized to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. If the trivalent vaccine can stimulate the patient’s immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars that are over expressed on the surface of most sarcomas, then the patient’s antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma. For more information about the trial, please visit the clinical trial overview.

AVE8062 for Soft Tissue Sarcoma

Sanofi aventis recently initiated a Phase III clinical trial for AVE8062 in patients with advanced-stage soft tissue sarcoma. AVE8062 (combretastatin derivative)  is a new vascular disruptive agent. Over recent years, in single agent and combination studies AVE8062 has been shown to dramatically decrease the tumor blood flow, resulting in anti-tumor efficacy, mainly in combination. For more information about the trial, please visit the clinical trial overview.

CP-751,871 for Ewing’s Sarcoma

Pfizer recently initiated a global Phase III clinical trial registration program for CP-751,871 in Ewing’s sarcoma. To date, more than 500 patients have participated in CP-751,871 clinical trials in multiple tumor types. For more information about the trial, please visit the clinical trial overview.

Sarcoma Alliance for Research through Collaboration (SARC)

SARC is a non-profit organization providing the infrastructure for collaboration between physicians, researchers, and medical institutions from across the world who are engaged in clinical research for development of new standards of patient treatment, education, and prevention. To find out more about SARC and a listing of our current clinical trials, please go to the Sarc Trials Website.

Brostallicin Clinical Trial for Myxoid Liposarcoma

Pharmatech, Inc. is managing a clinical trial sponsored by Systems Medicine, LLC.  The trial is a Phase 2 open-label clinical study of an experimental drug called Brostallicin, for the treatment of patients with myxoid liposarcoma with a (12;16) translocation. The cancer must be metastatic or unresectable and standard curative or palliative measures do not exist or are not effective. Patients with myxoid liposarcoma may wish to discuss the Brostallicin trial with their doctors to see if it may be right for them.  For more information about the trial and to find a participating trial site, please visit http://www.pharmatech.com/clinicaltrials.html or call 1-866-383-6610 x160 or email .(JavaScript must be enabled to view this email address).

Patient Resources

About Clinical Research
Background information about the clinical trials process and what to expect when you volunteer to participate in a clinical trial. Here, you’ll find answers to frequently asked questions about clinical trials and also suggestions for where to find more information.

CenterWatch Clinical Trials Listing Service
Database of industry sponsored clinical trial listings for Sarcoma.

Listing of Studies at ClinicalTrials.gov
Link to ClinicalTrials.gov, a comprehensive listing of federally and privately supported clinical trials. The U.S. National Institutes of Health (NIH), through its National Library of Medicine (NLM), has developed this site in collaboration with the Food and Drug Administration (FDA).

Profiles of Research Centers
Detailed descriptions of centers that conduct clinical research in the field of Oncology. Profiles include an overview of each center, descriptions of clinical research investigators and staff, and links to currently enrolling clinical research studies.

New FDA Drug Approvals
Database of new medical treatments approved by the FDA since 1995. Detailed summary descriptions for each drug are provided including drug name; manufacturer; mechanism of action; clinical trial results, and side effect profile.

CenterWatch Research Headlines
Here you’ll find links to news articles and reports on recent advances in clinical research. This section is updated weekly and the information has been published in CenterWatch publications during the past weeks.

CenterWatch Bookstore
Descriptions of all of CenterWatch’s publications for patients and for clinical research professionals.

Coalition of National Cancer Cooperative Groups
The Coalition’s website provides a wealth of information about cancer clinical trials. Website features include:

    • TrialCheck, a clinical trials search engine
    • Cancer Research: A Guide to Cancer Clinical Trials, an interactive educational program
    •   Print materials for ordering
    • Discussion with oncology experts
    • Patient discussion forum

Clinical Trials search site
The NCI has developed this premier site.  Just type in osteosarcoma, soft tissue sarcoma, etc., or refine the search to your personal interests

CancerTrialsHelp.org
This site supplements the NCI site above a little bit, but is incomplete so should not be your sole search site

Programs & Resources